Efficacy study of Sygnis's G-CSF in stroke under way
This article was originally published in Scrip
Executive Summary
The German company Sygnis Pharma expects clinical data from its Phase II study of its G-CSF product, AX200, in acute ischaemic stroke, to be available in the middle of 2011.